PIMAVANSERIN TARTRATE | A214493 | ZYDUS WORLDWIDE DMCC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
ACADIA Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. et al 4 patentsANDA 214493Pimavanserin tartrate | D. Del. | 2022-10-21 | Terminated 2023-04-05 | — |
ACADIA Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. et al 5 patentsANDA 214493, 214502pimavanserin | D. Del. | 2020-07-30 | Terminated 2023-04-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Zydus Pharmaceuticals (USA) Inc. FDA-2024-P-2514 · 4 docket documents Zydus Pharmaceuticals (USA) Inc. filed this petition on May 22, 2024, requesting that the FDA determine whether NUPLAZID (pimavanserin) tablets, 17 mg (NDA N207318), held by Acadia Pharmaceuticals Inc., was withdrawn from commercial sale for reasons of safety or effectiveness or for commercial reaso | 505(q) | 2024-05-23 | Granted | Zydus Pharmaceuticals (USA) Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.